Q-omics provides the consensus-scored WNT9B profile across patient tissues and cancer cell-line models. WNT9B expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, WNT9B is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, WNT9B RNA expression shows 12,623 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, and TGCT as cancer lineages where WNT9B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for WNT9B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes WNT9B survival associations across molecular data types. WNT9B RNA expression shows survival associations in the most cancer types (25), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible WNT9B RNA expression–survival associations across cancer types. High WNT9B expression shows unfavorable associations in DLBC, but favorable associations in KIRC, PAAD, SCLC, HNSC and LAML. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for WNT9B RNA expression.
This table summarizes WNT9B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for WNT9B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. WNT9B shows lower tumor expression in KIRC, KIRP, KICH, UCEC and BRCA and higher tumor expression in COAD. The KIRC box plot shows higher WNT9B RNA expression in normal versus tumor tissue (log2 FC = −2.436, t-test p < 0.001).
This table shows molecular features associated with WNT9B in patient tissues and cancer cell lines. In patient samples, WNT9B shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, WNT9B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in SKIN and LUNG_SCLC.
